Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

865 results

• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 26NCT01620190
• Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment: primary endpoint…Phase 2Results postedn = 44NCT00807573
• PACTIndependent statistical analysis and educational interpretation of PACT (NCT00272506), a phase 3 crossover trial evaluating inhaled corticosteroid and long-acting beta2-agonist therapy in pediatric asthma.Phase 3NCT00272506
• PACTIndependent statistical analysis of Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 30NCT06001398
• PAHIndependent statistical analysis of Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03638908).Phase 2Results postedn = 8NCT03638908
• Pain Control Following Sinus Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pain Control Following Sinus Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03783702).Phase 4Results postedn = 118NCT03783702
• Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 100NCT01006629
• Palu-COVIDIndependent statistical analysis of Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 238NCT05012280
• PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…Phase 3Results postedn = 445NCT00810693
• PATHOSIndependent statistical analysis of the PATHOS study (NCT01146392), examining COPD health care structure in primary care using medical record data collected over one decade.n = 27,394NCT01146392
• Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 33NCT01253369
• PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: Complete Statistical AnalysisIndependent statistical analysis of PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 60NCT05553834
• PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 1,821NCT04613375
• Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: Complete Statistical AnalysisIndependent statistical analysis of Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00944073).Phase 2Results postedn = 583NCT00944073
• Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 9NCT04032418
• Pembrolizumab in Combination With CRT for LA-SCCHN: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With CRT for LA-SCCHN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02586207).Phase 1Results postedn = 59NCT02586207
• Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 33NCT03242915
• Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 154NCT03322540
• Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 10NCT00259285
• Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 79NCT00950365
• PERFORMIndependent statistical analysis of Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma: primary endpoint results, effect estimate with confidence interval,…Phase 4Results postedn = 1,358NCT06372496
• PERFUSEIndependent statistical analysis of Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 7NCT01638468
• Peripheral Nerve Blocks for Above-the-knee Amputations: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Nerve Blocks for Above-the-knee Amputations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03404180).Phase 4Results postedn = 30NCT03404180
• PERSEPHONEIndependent statistical analysis of the PERSEPHONE phase 3 trial evaluating lunsekimig compared with placebo in adults with inadequately controlled eosinophilic chronic obstructive pulmonary disease. Includes trial design, endpoints, statistical methodology, planned analysis,…Phase 3n = 942NCT07190209
• Pertussis Infection in Adolescents and Adults With Prolonged Cough: Complete Statistical AnalysisIndependent statistical analysis of Pertussis Infection in Adolescents and Adults With Prolonged Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01597687).Phase NAResults postedn = 337NCT01597687
• Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 13NCT00544648
• Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00280735).Phase 2Results postedn = 75NCT00280735
• Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00590902).Phase 2Results postedn = 81NCT00590902
• Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 12NCT01524302
• Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 54NCT03257995
• Pharmacokinetic Alterations During ECMO: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Alterations During ECMO: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01938079).Phase NAResults postedn = 20NCT01938079
• Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 180NCT02968914
• Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 47NCT02231177
• Pharmacokinetics of Omadacycline in Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Omadacycline in Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04460586).Phase 4Results postedn = 9NCT04460586
• Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 48NCT03722472
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 36NCT00423592
• Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 38NCT05935332
• Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects: Complete Statistical AnalysisIndependent statistical analysis of Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 56NCT02991859
• Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 95NCT04902885
• Phase I Combination Ixabepilone + Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination Ixabepilone + Cisplatin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00832117).Phase 1Results postedn = 30NCT00832117
• Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 25NCT01999985
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 252NCT02608268
• Phase I/II Calcitriol in Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Calcitriol in Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00794547).Phase 1/2Results postedn = 34NCT00794547
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 88NCT03583086
• Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 33NCT00503971
• Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: primary endpoint results,…Phase 2Results postedn = 106NCT00100932
• Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 321NCT01355484
• PHOTOIndependent statistical analysis of Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 30NCT01822197
• Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura: Complete Statistical AnalysisIndependent statistical analysis of Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 9NCT00601848

← All therapeutic areas